Your browser is no longer supported. Please, upgrade your browser.
Settings
TROV TrovaGene, Inc. daily Stock Chart
TROV [NASD]
TrovaGene, Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own0.80% Shs Outstand29.71M Perf Week-10.38%
Market Cap20.50M Forward P/E- EPS next Y-0.82 Insider Trans17.10% Shs Float26.35M Perf Month-25.61%
Income-39.00M PEG- EPS next Q-0.24 Inst Own18.40% Short Float12.49% Perf Quarter-65.50%
Sales0.40M P/S51.25 EPS this Y-23.90% Inst Trans-2.44% Short Ratio8.35 Perf Half Y-77.00%
Book/sh0.34 P/B2.03 EPS next Y21.20% ROA-83.10% Target Price4.00 Perf Year-87.13%
Cash/sh0.97 P/C0.71 EPS next 5Y- ROE-173.60% 52W Range0.65 - 5.98 Perf YTD-67.14%
Dividend- P/FCF- EPS past 5Y-40.90% ROI-110.30% 52W High-88.46% Beta0.61
Dividend %- Quick Ratio3.30 Sales past 5Y8.10% Gross Margin- 52W Low6.15% ATR0.08
Employees53 Current Ratio3.30 Sales Q/Q0.00% Oper. Margin- RSI (14)34.66 Volatility9.39% 9.32%
OptionableYes Debt/Eq1.55 EPS Q/Q6.40% Profit Margin- Rel Volume0.60 Prev Close0.72
ShortableYes LT Debt/Eq1.19 EarningsMay 10 AMC Payout- Avg Volume394.26K Price0.69
Recom2.00 SMA20-15.89% SMA50-27.05% SMA200-74.65% Volume237,198 Change-4.46%
Apr-12-17Upgrade Maxim Group Hold → Buy $4
Mar-16-17Downgrade Piper Jaffray Neutral → Underweight
Mar-16-17Downgrade Maxim Group Buy → Hold
Aug-08-16Upgrade Cantor Fitzgerald Hold → Buy
Aug-05-16Reiterated Maxim Group Buy $12 → $9
Jul-07-16Initiated Maxim Group Buy $12
Apr-26-16Downgrade Leerink Partners Outperform → Mkt Perform
Apr-25-16Downgrade Piper Jaffray Overweight → Neutral
Apr-25-16Downgrade Cantor Fitzgerald Buy → Hold $9 → $5
Feb-03-16Reiterated Maxim Group Buy $13 → $12
Sep-16-15Initiated Cantor Fitzgerald Buy
Aug-14-15Initiated Leerink Partners Outperform
Apr-20-15Reiterated Maxim Group Buy $10 → $13
Jul-10-14Initiated Maxim Group Buy $10
Nov-13-13Reiterated Aegis Capital Buy $14 → $10
Oct-01-13Reiterated Aegis Capital Buy $14
Jul-16-13Initiated Cantor Fitzgerald Buy $10
Apr-01-13Reiterated Aegis Capital Buy $12 → $14
Dec-12-12Initiated Aegis Capital Buy $12
May-25-17 12:49PM  ETFs with exposure to TrovaGene, Inc. : May 25, 2017 Capital Cube
08:00AM  Phase 1 Safety Study Supports Planned Development of PCM-075 in AML PR Newswire
May-24-17 09:52AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-23-17 08:00AM  Trovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angeles PR Newswire -5.18%
May-10-17 07:14PM  Edited Transcript of TROV earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.14%
05:26PM  Trovagene reports 1Q loss Associated Press
04:05PM  Trovagene Announces First Quarter 2017 Company Highlights and Financial Results PR Newswire
Apr-26-17 08:00AM  Trovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 10, 2017 PR Newswire +5.77%
Apr-25-17 08:00AM  Trovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City PR Newswire
Apr-20-17 02:33PM  ETFs with exposure to TrovaGene, Inc. : April 20, 2017 Capital Cube
Apr-13-17 12:41PM  Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board PR Newswire +21.34%
Apr-07-17 05:38PM  ETFs with exposure to TrovaGene, Inc. : April 7, 2017 Capital Cube -10.00%
Mar-31-17 09:30AM  TrovaGene and NewLink Genetics Find Investors Optimistic About Products Accesswire
Mar-28-17 08:27AM  TROVAGENE, INC. Files SEC form 8-K, Regulation FD Disclosure
Mar-27-17 04:08PM  ETFs with exposure to TrovaGene, Inc. : March 27, 2017 Capital Cube +10.00%
04:08PM  ETFs with exposure to TrovaGene, Inc. : March 27, 2017
09:20AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene to Present at The MicroCap Conference on April 4, 2017 in New York City PR Newswire
Mar-21-17 01:04PM  TROVAGENE, INC. Financials -8.51%
09:36AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
09:29AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
09:29AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
08:00AM  Trovagene to Present at the Sidoti & Company Spring 2017 Convention PR Newswire
Mar-20-17 10:20AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017 -9.62%
Mar-16-17 10:17AM  TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4 Zacks -25.71%
06:50AM  TrovaGene downgraded by Piper Jaffray and Maxim Group
Mar-15-17 10:58PM  Edited Transcript of TROV earnings conference call or presentation 15-Mar-17 9:00pm GMT Thomson Reuters StreetEvents +6.06%
04:40PM  Trovagene reports 4Q loss Associated Press
04:25PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements
04:08PM  TROVAGENE, INC. Files SEC form 10-K, Annual Report
04:04PM  Trovagene Reports Fourth Quarter and Year End 2016 Financial Results PR Newswire
04:02PM  Trovagene and Nerviano Announce License Agreement for therapeutic candidate PCM-075 PR Newswire
07:07AM  Q4 2016 Trovagene Inc Earnings Release - After Market Close
Mar-07-17 10:13AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovera EGFR Urine Liquid Biopsy Test Predictive of Clinical Response to Therapy: Case Series in Patients with Non-Small Cell Lung Cancer PR Newswire
Mar-02-17 11:44AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Mar-01-17 08:00AM  Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and Accomplishments and Host Conference Call on Wednesday, March 15, 2017 PR Newswire
Feb-28-17 12:21PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene to Attend the 29th Annual ROTH Conference PR Newswire
Feb-15-17 07:50AM  TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy?
Feb-01-17 09:45AM  LD Micro Index Reconstitution as of February 1, 2017 Accesswire
Jan-24-17 09:50AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Publication of Trovera KRAS Liquid Biopsy Test Demonstrates Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response PR Newswire
Jan-12-17 11:59AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene Announces Broadening Network of Commercial Distributors PR Newswire
Jan-09-17 06:06AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Dec-19-16 02:20PM  ETFs with exposure to TrovaGene, Inc. : December 19, 2016
Dec-15-16 06:30AM  Trovagene to Focus More on Liquid Biopsy Testing Market
Dec-13-16 05:01PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
04:05PM  Trovagene announces a reorganization to accelerate global distribution of liquid biopsy technology PR Newswire
Dec-08-16 03:24PM  ETFs with exposure to TrovaGene, Inc. : December 8, 2016 +15.22%
Dec-01-16 08:31AM  TrovaGene Inks Contract with Boreal Genomics, Stock Down -12.07%
Nov-30-16 08:20AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene and Boreal Genomics Announce Strategic Partnership PR Newswire
Nov-29-16 08:56AM  TrovaGene (TROV) Precision Cancer Monitoring Data Positive
Nov-28-16 08:26AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  World Lung Conference Features Data Demonstrating Clinical Utility and Cost Effectiveness of Trovagene's Liquid Biopsy Tests for Mutation Detection and Monitoring in NSCLC Patients PR Newswire
Nov-22-16 08:43AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Trovagene to Attend the 28th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-16-16 01:30PM  ETFs with exposure to TrovaGene, Inc. : November 16, 2016 +8.47%
Nov-14-16 11:31AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-10-16 08:23AM  TrovaGene (TROV) Reports Wider-than-Expected Loss in Q3 -15.19%
12:12AM  Edited Transcript of TROV earnings conference call or presentation 9-Nov-16 10:00pm GMT
Nov-09-16 04:21PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition +11.27%
04:11PM  Trovagene reports 3Q loss
04:01PM  Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire
04:00PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q3 2016 Trovagene Inc Earnings Release - 4:00 pm ET
Nov-07-16 08:26AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +9.09%
08:00AM  Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office, Broadening Its Precision Cancer Monitoring IP Portfolio PR Newswire
Nov-02-16 05:12PM  Trovagene Schedules Release of Third Quarter 2016 Financial Results and Investor Conference Call PR Newswire -7.35%
05:02PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Oct-17-16 10:30AM  Trovagene to Present at the BIO Investor Forum in San Francisco on October 19 PR Newswire
Oct-05-16 08:42AM  Trovagene's Liquid Biopsy to Participate in Precision Promise
Oct-04-16 08:29AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
06:00AM  Trovagene's Liquid Biopsy in Groundbreaking National Initiative to Transform Outcomes for Pancreatic Cancer Patients PR Newswire
Sep-30-16 10:10AM  ETFs with exposure to TrovaGene, Inc. : September 30, 2016
Sep-26-16 06:04AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-12-16 12:00PM  ETFs with exposure to TrovaGene, Inc. : September 12, 2016
Sep-09-16 09:03AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.05%
08:30AM  Trovagene to Present at the 3rd Annual Precision Medicine Congress PR Newswire
Aug-31-16 11:56AM  ETFs with exposure to TrovaGene, Inc. : August 31, 2016
Aug-17-16 10:50AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:30AM  Blue Cross Blue Shield Illinois to Cover Trovera Liquid Biopsy Tests PR Newswire
Aug-16-16 12:47PM  ETFs with exposure to TrovaGene, Inc. : August 16, 2016
Aug-15-16 01:42PM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-09-16 11:01AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:34AM  Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference PR Newswire
08:30AM  Trovera Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer PR Newswire
Aug-06-16 02:21PM  Edited Transcript of TROV earnings conference call or presentation 4-Aug-16 9:00pm GMT
Aug-05-16 08:33AM  TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise -5.63%
Aug-04-16 07:37PM  Trovagene reports 2Q loss
05:12PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments PR Newswire
04:09PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2016 Trovagene Inc Earnings Release - 4:00 pm ET
Aug-01-16 10:11AM  Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Jul-26-16 04:32PM  TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
08:45AM  Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call PR Newswire
08:30AM  Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology PR Newswire
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Erlander MarkChief Scientific OfficerJan 02Option Exercise0.0050,000055,000Jan 04 05:01 PM
Tennant StanleyDirectorDec 19Buy2.1010,00021,000217,728Dec 19 04:51 PM
Tennant StanleyDirectorDec 16Buy2.0014,96629,932207,728Dec 19 06:04 AM
WELCH WILLIAM JCEODec 16Buy2.094,7509,9444,750Dec 19 01:49 PM
Erlander MarkChief Scientific OfficerDec 14Buy2.085,00010,3755,000Dec 15 05:00 PM